SI1748781T1 - Postopki za zdravljenje motenj krvavenja ob uporabi sulfatiranih polisaharidov - Google Patents

Postopki za zdravljenje motenj krvavenja ob uporabi sulfatiranih polisaharidov

Info

Publication number
SI1748781T1
SI1748781T1 SI200531664T SI200531664T SI1748781T1 SI 1748781 T1 SI1748781 T1 SI 1748781T1 SI 200531664 T SI200531664 T SI 200531664T SI 200531664 T SI200531664 T SI 200531664T SI 1748781 T1 SI1748781 T1 SI 1748781T1
Authority
SI
Slovenia
Prior art keywords
methods
sulfated polysaccharides
bleeding disorders
treating bleeding
treating
Prior art date
Application number
SI200531664T
Other languages
English (en)
Inventor
Kirk W. Johnson
Original Assignee
Baxter International Inc.
Baxter Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Baxter Healthcare S.A. filed Critical Baxter International Inc.
Publication of SI1748781T1 publication Critical patent/SI1748781T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200531664T 2004-05-27 2005-05-27 Postopki za zdravljenje motenj krvavenja ob uporabi sulfatiranih polisaharidov SI1748781T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides
EP05765950A EP1748781B1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
SI1748781T1 true SI1748781T1 (sl) 2013-03-29

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531664T SI1748781T1 (sl) 2004-05-27 2005-05-27 Postopki za zdravljenje motenj krvavenja ob uporabi sulfatiranih polisaharidov

Country Status (16)

Country Link
US (4) US7767654B2 (sl)
EP (2) EP1748781B1 (sl)
JP (2) JP5232470B2 (sl)
CN (2) CN1984664B (sl)
AU (1) AU2005249465B2 (sl)
BR (1) BRPI0511603A (sl)
CA (1) CA2567495C (sl)
CY (1) CY1113705T1 (sl)
DK (1) DK1748781T3 (sl)
ES (2) ES2399277T3 (sl)
HK (2) HK1103624A1 (sl)
PL (1) PL1748781T3 (sl)
PT (1) PT1748781E (sl)
RU (1) RU2347574C2 (sl)
SI (1) SI1748781T1 (sl)
WO (1) WO2005117912A1 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PT1748781E (pt) * 2004-05-27 2013-01-22 Baxter Int Processos para o tratamento de distúrbios de hemorragias utilizando polissacarídeos sulfatados
CA2648533A1 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides
KR101486931B1 (ko) 2007-02-23 2015-01-27 박스터 인터내쇼날 인코포레이티드 해조류 추출물로부터 푸코이단을 정제하는 방법
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
AU2009284393B2 (en) * 2008-08-22 2014-09-25 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders
CA2746257C (en) * 2008-12-11 2018-01-16 Baxter International Inc. Preparations based on fibrinogen and sulfated polysaccharides
AU2009327338B2 (en) * 2008-12-19 2015-07-02 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CA2786758A1 (en) 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
WO2011131720A1 (en) * 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
EP2624859B1 (en) 2010-10-06 2017-03-01 Medimmune Limited Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
CN103841979B (zh) * 2011-07-19 2019-01-11 百深有限责任公司 作为改善非抗凝血的硫酸多糖的口服制剂的添加剂的吸收促进剂
US20130209444A1 (en) * 2012-01-30 2013-08-15 Baxter Healthcare S.A. Non-anticoagulant sulfated or sulfonated polysaccharides
US20130202550A1 (en) * 2012-01-30 2013-08-08 Baxter Healthcare S.A. Non-anticoagulant sulfated or sulfonated synthetic polymers
NZ724133A (en) 2012-03-21 2020-07-31 Baxalta Inc Tfpi inhibitors and methods of use
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
EP3594686A3 (en) * 2012-08-14 2020-04-08 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
SG11202001824RA (en) * 2016-08-31 2020-04-29 Oji Holdings Corp Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
BR112019025030A2 (pt) 2017-05-31 2020-06-16 Oji Holdings Corporation Preparação umidificante tópica.
BR112020004787A2 (pt) 2017-09-12 2020-09-24 Oji Holdings Corporation polissulfato de pentosano, composição farmacêutica, anticoagulante, e, método para produzir polissulfato de pentosano
CN111511773B (zh) 2017-12-20 2023-01-13 王子控股株式会社 戊聚糖多硫酸酯以及含有戊聚糖多硫酸酯的药物
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
CA2070813C (en) * 1990-11-05 1996-10-29 Hendrik Coenraad Hemker A method to determine the concentration of anticoagulants
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
KR100414607B1 (ko) * 1995-04-28 2004-07-23 리서치 인스티튜트 포 글리코테크놀로지 당화합물
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
AU729843B2 (en) * 1997-04-25 2001-02-08 Dsm Ip Assets B.V. Method for the functional detection of disorders in the protein C system
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
JP4261071B2 (ja) * 1999-04-15 2009-04-30 タカラバイオ株式会社 治療剤
EP1279405A1 (en) * 2000-03-30 2003-01-29 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
ATE386538T1 (de) * 2001-02-05 2008-03-15 Novo Nordisk Healthcare Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
ES2236420T3 (es) * 2001-10-24 2005-07-16 Takara Bio Inc. Oligosacarido de fucano sulfatado.
JP3941036B2 (ja) * 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) * 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
PT1748781E (pt) * 2004-05-27 2013-01-22 Baxter Int Processos para o tratamento de distúrbios de hemorragias utilizando polissacarídeos sulfatados
CA2648533A1 (en) 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides

Also Published As

Publication number Publication date
US20050282771A1 (en) 2005-12-22
DK1748781T3 (da) 2013-02-11
CY1113705T1 (el) 2016-06-22
US20120129777A1 (en) 2012-05-24
EP1748781A4 (en) 2008-07-02
CA2567495A1 (en) 2005-12-15
US7829549B2 (en) 2010-11-09
CN1984664B (zh) 2013-07-24
AU2005249465B2 (en) 2007-12-06
US20110237512A1 (en) 2011-09-29
US7767654B2 (en) 2010-08-03
BRPI0511603A (pt) 2008-01-02
EP2165711A1 (en) 2010-03-24
JP2012046551A (ja) 2012-03-08
HK1103624A1 (en) 2007-12-28
RU2347574C2 (ru) 2009-02-27
RU2006146801A (ru) 2008-07-10
US8859526B2 (en) 2014-10-14
PL1748781T3 (pl) 2013-05-31
CN1984664A (zh) 2007-06-20
EP1748781A1 (en) 2007-02-07
EP1748781B1 (en) 2012-12-19
ES2399277T3 (es) 2013-03-27
US8771973B2 (en) 2014-07-08
JP5232470B2 (ja) 2013-07-10
ES2482105T3 (es) 2014-08-01
US20090269325A1 (en) 2009-10-29
AU2005249465A1 (en) 2005-12-15
PT1748781E (pt) 2013-01-22
CN103251647A (zh) 2013-08-21
CA2567495C (en) 2014-02-18
HK1142276A1 (en) 2010-12-03
WO2005117912A1 (en) 2005-12-15
EP2165711B1 (en) 2014-05-21
JP2008500367A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
HK1142276A1 (en) Methods for treating bleeding disorders using sulfated polysaccharides
EP1855710A4 (en) MUSCLE REGENERATION
PL1951030T3 (pl) Udoskonalone sposoby i środki do wytwarzania hialuronianu
ZA200705459B (en) Treatment method
PL1805312T3 (pl) Sposoby i środki do wytwarzania hialuronianu
GB0526291D0 (en) Therapeutic method
GB0506759D0 (en) Combination treatment methods
EP1797020A4 (en) GUANIDINE POLYSACCHARIDES, THEIR USE AS ABSORBENTS AND PROCESS FOR THE PRODUCTION THEREOF
IL182011A0 (en) Treatment screening methods
IL187450A0 (en) Methods for treating fibrotic conditions
IL183985A0 (en) Methods for treating autoimmune disorders
EP1912658A4 (en) THERAPEUTIC PROTOCOLS WITH HYALURONANE
EP1755670A4 (en) METHODS FOR TREATING VASCULAR DISEASES
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
PT1686201E (pt) Aparelho de pulling-down
GB0518232D0 (en) New methods
EP1952821A4 (en) THERAPEUTIC AGENT FOR REGENERATING THE DENTIN-PULPA COMPLEX
EP1942909A4 (en) METHODS OF TREATING RESPIRATORY DISORDERS
GB0502171D0 (en) Well treatment
EP1928498A4 (en) METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
ZA200709915B (en) Methods for treating fibrotic conditions
GB0513777D0 (en) Methods for tissue engineering
ZA200803971B (en) Improved methods and means for producing hyaluronan